Re: Farmas USA
Re: Farmas USA
NVAX hoy +17.25%
Novavax (NVAX): Reiterating $12 PT After Management Meeting - FBR
January 18, 2017 7:34 AM EST T
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Novavax (NASDAQ: NVAX) after meeting with management and hearing about development plans for 2017.
The analyst is focused on the small safety study using revised RSV vaccine dosing regimens that is planned for initiation later in 1Q17 (estimated top-line data in 3Q17) as one that will confirm the
vaccine’s path toward possible regulatory approval. The value of the Phase III maternal RSV vaccine remains largely under-recognized for its potential to be a catalyst for the stock (estimated top-line data in late 4Q17). With the identification of a Zika virus (ZIKV) preclinical vaccine candidate, the analyst thinks NVAX could emerge as a leading developer of a ZIKV vaccine in 2H17
Re: Farmas USA
Re: Farmas USA
te han intimididado aqui?
Re: Farmas USA
Re: Farmas USA
no creo que eso de FBR tenga que ver ya que es old news ni lo que comenta Seeking Alpha hoy ( http://seekingalpha.com/news/3243618-novavaxs-mid-stage-study-rsv-vaccine-candidate-poised-start-shares-ahead-18-percent ) que tambien es old news ...
Sube por que a algun fondo le tocaba cubrirse y ya conocemos todos los mvtos chicharreos ... PUMP and ... bueno, ya lo veremos ...
NVAX